ev3 Inc

ev3 — Foxhollow Technologies — Merger or Acquisition (September 2007)

26 slides from ev3's merger presentation, Sep 10, 2007

  1. Slide 1: September Update 2007

    September Update 2007 Jim Corbett CEO

  2. Slide 2: Forward-Looking Statements

    This presentation contains "forward-looking statements" about ev3 and FoxHollow within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the benefits of the business combination transaction involving ev3 and FoxHoll

  3. Slide 3: Forward-Looking Statements (continued)

    The following factors, among others, could cause actual results to differ materially from the anticipated results or other expectations expressed in the forward-looking statement: general business and economic conditions; the ability to obtain governmental approvals of the transaction on a timely ba

  4. Slide 4: Consistent Revenue Growth

    Consistent Revenue Growth Last 5 Quarters Annual Q3 Q4 Q1 Q2 51.9 57.7 61.5 50.6 65.4 1st Qtr 2nd Qtr 3rd Qtr 4th Qtr East 37 68 86 134 202.4 50%+ CAGR $ Millions +29% $37 $68 $86 $134 $202 02 03 04 05 06 $51.9 $57.7 $61.5 $65.4 Q3 Q4 Q1 $ Millions Q2 $50.6 2006 2007

  5. Slide 5: Balanced Revenue Growth

    Balanced Revenue Growth Q3 Q3 Q1 Q2 31.1 34.6 35.1 30.7 39.6 +29% $31.1 $34.6 $35.1 Q3 Q4 Q1 Q2 $39.6 $30.7 +30% +24% +33% Total U.S. Total International Worldwide Cardio Peripheral Worldwide Neurovascular Revenues ($ Millions) Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 20.7 23.7 25 20 24.8 Q3 Q4 Q1 Q2 20.8 23.1 26.4

  6. Slide 6: ev3 Growth Drivers

    ev3 Growth Drivers 2007 Market ev3 Product Protege ev3 Estimates $150M

  7. Slide 7: Cardio Peripheral

    ge ev3 THE ENDOVASCULAR COMPANY Cardio Peripheral

  8. Slide 8: ev3 Carotid Stent and SpiderFX U.S. Launch

    Protege Stent Guidewire External Carotid Artery Internal Carotid Artery SpiderFX Filter ev3 Carotid Stent and SpiderFX U.S. Launch Q1 '07

  9. Slide 9: Stents Fracture in Multiple Ways

    Stents Fracture in Multiple Ways

  10. Slide 10: Clinical Research in the SFA: A Strategic Commitment

    Clinical Research in the SFA: A strategic Commitment- Durability II - SFA FDA Trial 30 sites, 287 patients 30 day MAE, 3 month, 6 month, annually for 5 years Primary endpoints, patency and fracture at 1 year Lesions treated 7-16 CM Durability I- European Efficacy Trial Enrollment Completed 152 patie

  11. Slide 11: Neurovascular

    ge ev3 THE ENDOVASCULAR COMPANY Neurovascular

  12. Slide 12: Axium Detachable Coil System

    Linear Release System Axium(tm) Detachable Coil System Axium 3D Coil Unique Implant Design Optimized for softness and packability Conformable and stable coil design Platinum and Surface Modified Instant Reliable Detachment Single handed actuator Simple, elegant design WW Detachable Coil Opportunity

  13. Slide 13: Brain AVM

    Brain AVM Angio confirms arteriovenous malformation Final angiogram: patient well, no surgery, back to work, no deficit

  14. Slide 14: Hemorrhagic and Ischemic Stroke; SOLO Neurovascular Stent

    Hemorrhagic Stroke Aneurysm neck bridging WW Market Opportunity 2005 2010 CAGR $25M $65M 20%+ Ischemic Stroke Stenotic disease Clot retrieval Flow restoration WW Market Opportunity 2005 2010 CAGR $5M $260M 100%+ SOLO(tm) Neurovascular Stent Platform Product Self expanding neurovascular stent Placed

  15. Slide 15: Financial Overview

    ge ev3 THE ENDOVASCULAR COMPANY Financial Overview

  16. Slide 16: Improved Operating Performance

    Improved Operating Performance 1st Qtr 2nd Qtr 3rd Qtr 4th Qtr East 37 68 86 134 202.4 Increasing Sales Force Productivity EBITDA, Excluding SBC Consistent Revenue Growth Improving Gross Margin Q4 '04 Q4 05 Q4 06 Q1 07 Q2 07 -21.1 -16.5 3 -1.8 -3.5 $(16.5) $3.0 59.5% Q2 05 Q2 06 Q2 07 59.5 64.1 65.8

  17. Slide 17: Creating a Global Leader in Endovascular Devices

    CREATING A GLOBAL LEADER IN ENDOVASCULAR DEVICES

  18. Slide 18: Important Additional Information for Investors and Stockholders

    Important Additional Information for Investors and Stockholders This communication is being made in respect of the proposed business combination involving ev3 and FoxHollow. In connection with the proposed transaction, ev3 filed with the SEC a registration statement on Form S-4, containing an inform

  19. Slide 19: Participants in the Solicitation

    Participants in the Solicitation ev3, FoxHollow and their respective directors and executive officers and other persons may be deemed to be participants in the solicitation of proxies from the stockholders of FoxHollow in respect of the proposed transaction. Information regarding ev3's directors and

  20. Slide 20: Use of Non-GAAP Financial Measures

    Use of Non-GAAP Financial Measures In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), ev3 uses the non-GAAP financial measures, such as "adjusted EPS" as supplemental measures of performance and believes these measures facilitate operat

  21. Slide 21: The Union of Need and Solution: The PAD Challenge

    The union of need and solution MINIMALLY INVASIVE SOLUTIONS THE PAD CHALLENGE PTA $235 M Atherectomy $200 M Stents $635 M Total Prevalence 8 million people Receive Treatment 2 million No Treatment 6 million Estimated 2007 US Market Size Estimated US Prevalence 1st Qtr 2nd Qtr 3rd Qtr 4th Qtr East 2

  22. Slide 22: Diverse Endovascular Product Offering

    Diverse Endovascular Product Offering Best-in-Class Solutions For Peripheral Vascular Disease Stents Everflex Everflex Long Nanoflex* Primus Protege Rx Protege Biggs PTA ..014 ..018 ..035 Longs and large diameters Atherectomy SilverHawk Plaque Excision System TurboHawk RockHawk NightHawk Embolic Pro

  23. Slide 23: Transaction Overview

    Transaction Overview Fourth Quarter of 2007 FoxHollow stockholders, customary closing conditions and anti- trust clearance, including HSR Warburg Pincus and The Vertical Group, together owning 56.8% of ev3 shares, have approved ev3's issuance of shares in connection with the transaction and the amen

  24. Slide 24: Guidance

    Guidance Revenues: 2008: In the range of $585-$615 million 2009: In the range of $700-$750 million Projected EPS*: 2008: In the range of $0.60 - $0.70 2009: In the range of $0.90 - $1.10 Including the impact of new and existing amortization expense, excluding the impact of one-time costs related to

  25. Slide 25: Creating a Global Leader in Endovascular Devices

    CREATING A GLOBAL LEADER IN ENDOVASCULAR DEVICES

  26. Slide 26: The Endovascular Company

    ge ev3 THE ENDOVASCULAR COMPANY

Foxhollow Technologies — Merger or Acquisition (September 2007) on 6ix